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Abstract: Background:The long-termeffect of excess iron deposition in the liver include fibrosis and cirrhosis which may progress to 
hepatocellular carcinoma. We assessed iron parameters among patients with chronic viral hepatitis B and C infection (CVHBI; CVHCI) to 
determineif any correlation existed with the degree of fibrosis in the liver. 
Methods: A cross-sectional descriptive study was carried out on 186 patients, made up of 132 patients withCVHBI and 54 patients with CVHCI. 
Serum ferritin and C-reactive protein were done by ELISA, serum iron and total iron binding capacity (TIBC) by colorimetric technique while 
transferrin saturation (Tsat) was calculated using serum iron and TIBC values. Liver fibrosis was assessed using fibroscan.Obtained data 
wereanalysed using SPSS version 20 and p values < 0.05 were considered statistically significant.   
Results: The mean values for serum ferritin, iron, TIBC and Tsat were 218.1±325.6µg/L, 25.1±22.8µmol/L, 71.13 ± 35.92µmol/L and 45.2 ± 
49.9% respectively. There were no significant differences in iron parameters between patients with CVHBI and CVHCI. Elevated serum ferritin 
was found in 15.2% and 20.4% of CHBVI and CHCVI patients respectively; while an elevated Tsat was seen in 22.7% and 24.1% of CHBVI 
and CHCVI patients respectively. Using a combination of elevated serum ferritin and Tsat, the prevalence of iron overload was found to be1.6%. 
Fibroscan scores did not differ significantly between patients with orwithout elevated iron parameters.  
Conclusion:Chronic viral hepatitis infection is associated elevated iron parameters though withminimal effect on liver fibrosis. 
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INTRODUCTION 
Chronic viral hepatitis is the main cause of liver cirrhosis 
and hepatocellular carcinoma (HCC) world over.
1
It is 
defined as persistent hepatic inflammation with or without 
periportal necrosis, for over six months from a viral 
aetiology.
2
 Implicated viruses include Hepatitis B virus 
(HBV) and Hepatitis C virus (HCV).   In Jos, Nigeria, the 
sero-prevalencerates of Hepatitis B surface antigen (HBsAg) 
and anti-HCV are as high as 15.1% and 4.3% 
respectively.
3
Replication of these viruses occurs mainly in 
the liver and also in lymphocytes, spleen and kidneys.
4 
 
Iron is an important factor in the replication of all organisms 
including virulent micro-organisms. The role of the liver is 
central to iron homeostasis as it serves both storage and 
synthetic functions. Within the hepatocytes, sinusoidal 
mesenchymal cells and reticuloendothelial cells of the liver 
are about one-third of the total body iron.
5
 Transferrin, 
ferritin and hepcidin which are important in iron transport 
and regulation are synthesized in the liver.
5
 Any form of 
liver dysfunction will disturb its functions as well iron 
homeostasis. This is even more pronounced when excess 
iron accumulates in the liver.
6
Elevated serum iron, 
transferrin saturation and ferritin levels have been noted in 
different studies on patients with chronic viral hepatitis 
infection. These findings have been linked to an up-
regulation of ferroportin due to low levels of hepcidin, with 
increased export of iron from enterocytes and macrophages.
7 
Some studies have associated hyperferritinaemia with poor 
response to antiviral therapy such as interferon alpha; viral 
persistence and progression to HCC in chronic carriers of 
HBV and HCV.
8-10
 The role of venesection in lowering 
serum iron with resultant improvement in liver function test 
in chronic viral hepatitis has also been documented.
11
 At 
large, excess iron portends a poor prognosis in chronic viral 
hepatitis. However, most of these studies have been carried 
out in the western countries, hence this study in a Nigerian 
population. 
 
MATERIALS AND METHODS 
Patients were consecutively enrolled from the 
Gastroenterology clinic in Jos University Teaching Hospital 
(JUTH) after ethical clearance was granted. Chronic viral 
hepatitis infection was confirmed by positive Hepatitis B 
surface antigen (HBsAg), positive antibody to Hepatitis B 
core antigen (anti-HBc) and negative Immunoglobulin M 
anti-HBc (IgM anti-HBc) for chronic HBV infection by 
immuno-chromatography (LumiQuick diagnostics, 
California, USA).Patients who tested positive for antibody 
to Hepatitis C virus (anti-HCV) were considered has having 
chronic HCV infection. Patients on antiviral therapy, who 
had been transfused or had a high serum C-reactive protein 
value were excluded from the study. Venous blood 
specimen was collected (in fasting state) into a sterile iron-
free plain bottle and allowed to clot within 1-2 hours at 
room temperature. This was then centrifuged to obtain 
serum and separated into a fresh iron-free plain bottle for 
analysis(stored at -20ᴼC until required for use).Serum iron 
indices (iron, total iron-binding capacity (TIBC), and 
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ferritin) were measuredfor each patient. Serum iron and 
TIBC were measured by immuno-turbidimetric method 
(Teco diagnostics, California, USA). Serum ferritin was 
done using ELISA technique (MonobindInc, Carlifornia 
USA). Transferrin saturation was calculated and expressed 
as a percentage of the totaliron-binding capacity (serum 
iron/TIBC x 100%). The transient elastography (fibroscan) 
pattern was determined on the Echosens 402 machine and 
values expressed in kilopascals (kPa). All patients were then 
graded as no/minimal fibrosis, moderate fibrosis, severe 
fibrosis, and advanced fibrosis/cirrhosis using the machine 
score card. The data obtained was analyzed using SPSS 
version 20.0 statistical package.  
RESULTS 
We evaluated a total of 186 patients, comprising 132 with 
CVHBI and 54 with CVHCI between January and October 
2017. The demographic and laboratory data are presented in 
Table 1.The mean (± SD) age of the study population was 
43 ± 13years with M:F ratio of 1.2:1. Mean values for serum 
ferritin, iron, TIBC and Tsat were 218.1±325.6µg/L, 
25.1±22.8µmol/L, 71.13± 35.92µmol/L and 45.2 ± 49.9% 
respectively. Iron parameters did not differ significantly 
between males and females, as well as between the young (≤ 
45years) and old (≥46years) age groups (p>0.05).There were 
no statistically significant differences in iron parameters 
between patients with CVHBI and CVHCI (p>0.05). 
Elevated serum ferritin was found in 15.2% and 20.4% of 
CVHBI and CVHCI patients respectively; while an elevated 
Tsat was seen in 22.7% and 24.1% of CVHBI and CVHCI 
patients respectively. Using a combination of elevated 
serum ferritin and Tsat, the prevalence of iron overload was 
1.6%. No statistically significant difference in the 
prevalence of iron overload between patients with CVHBI 
and CVHCI (1.5% versus 1.9%) was noted (t = 0.17, p = 
0.87). Figure 1a shows the comparison of the degree of 
fibrosis among patients with CVHBI and CVHCI while 
figures 1b to 1e show the correlation between serum ferritin, 
serum iron, Tsat, TIBC and fibroscan scores in the studied 
population. No significant correlation was found between 
the parameters and fibroscan score.Mean fibroscan score 
was 11.3 ± 13.3kPa with no significant difference in both 
populations (p>0.05). Fibroscan scores corresponding to 
no/minimal fibrosis was found in 58.1%, moderate fibrosis 
in 7%, severe fibrosis in 12.9% and advanced 
fibrosis/cirrhosis in 22% of patients investigated. Fibroscan 
scores did not differ significantly between patients 
with/without elevated iron parameters (p > 0.05).A weak 
and non-significant correlation was noted between fibroscan 
scores and serum ferritin (r = -0.11; p = 0.12) as well as Tsat 
(r = -0.11; p = 0.13), serum iron (r = -0.06; p = 0.38) and 
TIBC (r = 0.02; p = 0.74).  
Table 1: Demographic and laboratory data of patients 
Parameter 
(Mean ± SD)  
Total CVHBI CVHCI  T      P 
 
    
Age(yrs)  43±13 40±13 51±11  -      -     
M:F ratio 1.2:1 1.4:1 1:1.3  -      -     
Serum iron (µmol/L) 25.1±22.8 25.4±22.8 24.3±22.9  0.29      0.77     
SerumTIBC (µmol/L) 71.1±35.9 72.58±36.54 67.55±34.40  0.87      0.39     
Tsat (%) 45.2±49.9 44.3±47.7 47.5±55.3  0.40      0.69     
Serum Ferritin (µg/L) 218±325.6 206.1±308.4 247.5±365.7  0.79      0.43     
Fibroscan score(kPa) 11.3±13.3 10.5±12.6 13.2±14.9  1.25      0.36     
 
 
Figure 1a: Comparison of the degree of fibrosis among patients with CVHBI and CVHCI 
Key: 
F0-F1: No/Minimal fibrosis (HBV 0-6.9kPa; HCV 0-7.9kPa) 
F2: Moderate fibrosis (HBV 7-7.9kPa; HCV 8-8.9kPa) 
F3: Severe fibrosis (HBV 8-11kPa; HCV 9-14.5kPa) 
F4: Advanced fibrosis/Cirrhosis (HBV ≥11kPa; HCV ≥14.6kPa) 
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Figures1b – 1e: Correlation between fibroscan scores and ferritin, iron, TIBC, Tsat 
DISCUSSION 
The mean ferritin values found for patients with CVHBI and 
CVHCI were similar to what Olmez et al and Vaguet al 
independently reported while studying CVHBI and CVHCI 
patients respectively.
12, 13
 The mean ferritin value for black 
patients with CVHCI who participated in the National 
Health and Nutritional Examination Survey (NHANES) in 
USA was also comparable to the finding in this study.
14
 
Serum iron values found in patients with CHBVI in this 
study was at variance with what Mao et al reported for 
cirrhotic and non-cirrhotic patients with CVHBI in China.
6
 
Won and his colleagues in Seongnam, Korea found CVHCI 
patients with higher values of serum iron than what was 
observed in this study.
15
 The works of  Vaguet al in 
Romania, and Lin et al in China also yielded higher iron 
values than in this study.
13, 16
 No local data was found for 
comparison. The study by Won et al appeared to rule out the 
role of HFE gene mutation as a contributory factor to iron 
loading. They found no difference between carriers of the 
H63D mutation and those without in terms of serum and 
hepatic iron parameters.
15
From the aforementioned, an 
explanation on why these Caucasian populations have 
higher iron than Africans may then be linked to other 
unidentified genetic characteristics they bear or their dietary 
preferences. A difference in assay methods employed by 
these studies may also be implicated.Buyukasiket al studied 
38 patients chronically infected with HBV or HCV 
alongside cirrhotic patients and healthy controls. The 
reported values for TIBC in those with chronic viral 
hepatitis were higher than the findings in this study but Tsat 
values were similar in both studies.
17
 The findings of this 
study for Tsat were also in agreement with that of Di-
Bisceglieet al in 1992 when an equal proportion of patients 
with CVHBI and CVHCI were evaluated for iron status.
18
 
 
The finding of more elevated iron indices in CVHCI than 
CVHBI patients in this study was in keeping withthe reports 
of Arber et al, Prieto et al and Sajeevanet al.
19-21
 However, 
Buyukasik et al had a different report from that of this 
study. There was no difference in iron parameters among the 
patients they studied, perhaps due to their smaller study 
population.
17 
 
A disparity in the criteria for iron overload assessment 
exists. The prevalence of iron overload in this study was 
determined by simultaneously high serum ferritin and Tsat 
levels in patients. Although this is the ideal in iron overload 
assessment, most authors defined iron overload by elevation 
of either parameter.
22, 23
In this study, the prevalence of iron 
overload in patients with chronic viral hepatitis was 1.6%. 
This prevalence is low when compared to the report of Di-
Biscelgieet al (39%) who used similar criteria for iron 
overload assessment.
18
This may be due to the higher 
prevalence of the haemochromatosis gene among whites 
than blacks. Fasolaet al in identifying healthy Nigerian 
women with iron overload used only an elevated Tsat level 
above 50% and reported a prevalence of 8.6%.
24
 When 
compared to the aforementioned, the prevalence of iron 
overload (using a high Tsat level only) was higher in both 
CVHBI (22.7%) and CVHCI (24.1%) patients in this study. 
Buyukasiket al also used a Tsat cut off of 50% for iron 
overload assessment.
17
 They however found no one with 
iron overload among their subjects with chronic viral 
hepatitis infection.
17
 Though some authors have also 
considered hyperferritinaemia as being diagnostic of iron 
overload, a major drawback that must be checked is the role 
of ferritin as an acute phase reactant.
25
 An elevated ferritin 
level may then be observed in acute inflammatory states 
making it unreliable.
25
Okeke reported the prevalence of 
hyperferritinaemia to be 50% among intending blood donors 
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with HCV infection in Enugu, Southeast Nigeria.
26
 This was 
higher than the finding in this study (15.2% among CVHBI 
and 20.4% among CVHCI patients). Okeke used fewer 
subjects for his study. This may account for the higher value 
he reported. Also, ferritin values were not controlled with 
another acute phase reactant such as was done in this 
study.
26
 CVHCI patients in this study had a higher 
prevalence of iron overload whether high levels of ferritin 
and Tsat are employed singly or combined. There are 
limited reports on the comparison of iron overload 
occurrence in CVHBI and CVHCI.  There is therefore room 
for further research on this subject matter.  
 
There were weak negative correlations between fibroscan 
scores and serum ferritin, iron, and Tsat. A weak positive 
correlation was noted between fibroscan scores and TIBC. 
None of these associations were statistically significant. 
Previous studies comparing iron status with degree of liver 
fibrosis have used liver histology, liver ultrasound scan 
and/or biochemical plus clinical parameters in assessing the 
presence of liver fibrosis/cirrhosis.
6, 27
This is because 
fibroscan is a relatively new technique for this purpose. 
Some authors have assessed the reliability of fibroscan 
scores and found it to be accurate when compared to liver 
histology reports.
28,29
Verveeret al shared the same opinion 
but noted that it was suboptimal in assessing fibrosis for 
stages ≤ F2.30 Liang et al opined that a combination of 
fibroscan scores with other biochemical parameters as well 
as liver ultrasound scan improves accuracy in liver cirrhosis 
confirmation among CVHBI carriers.
31
  It may be inferred 
that the findings of this study were similar to the reports of 
Mao etal and Lin et al in which they used liver histology 
and a combination of radio-biochemical parameters 
respectively to assess liver fibrosis.
6, 16 
 The finding in this 
study was, however, different from the report of Vaguet al.
13
 
They employed only biochemical parameters in determining 
severity of liver disease and only CVHCI patients were 
studied.
13
 Most researchers have however observed a 
positive association between iron status and biochemical 
markers of liver disease such as alanine transaminase (ALT) 
as well as aspartate transaminase (AST) in both CVHBI and 
CVHCI patients.
32, 33
 This was however not assessed in this 
study because of the non-specificity of the elevation of these 
enzymes to liver disease.
34
 Besides, some patients with 
chronic viral hepatitis infection may not have elevated liver 
enzymes.
35
 
 
This study found minimal effect of iron overload on the 
degree of liver fibrosis. The few patients with iron overload 
all had no/minimal fibrosis from their fibroscan score 
assessment. Most patients with either a high Tsat or ferritin 
also had no/minimal liver fibrosis.  There was no difference 
in the severity of liver fibrosis between patients with and 
without iron overload. Most researchers that investigated the 
influence of iron overload on liver fibrosis severity relied on 
the pattern and extent of iron stain as well as the degree of 
fibrosis from liver biopsy specimens for their judgement.
36, 
37
 However, Metwallyet al compared both serum ferritin 
levels and hepatic iron deposition in assessing an influence 
on the degree of liver fibrosis among only CVHCI 
patients.
38
 They concluded that there was a strong 
correlation between serum ferritin levels and hepatic iron 
content. They also opined that serum ferritin was an 
independent predictor of severe hepatic fibrosis.
38
It 
therefore brings to bare the disparity in the finding of this 
study in relation to others. Even though they used a 
histological assessment, it is expected either way that iron 
overload should worsen liver fibrosis due to the hepatotoxic 
nature of excess iron on the liver.
39
 The difference in 
findings may be linked to the sensitivity of the method 
employed to assess liver fibrosis in this study. Further 
studies to assess the sensitivity of liver transient 
elastographyin comparison to liver histologic findings in 
chronic viral hepatitis especially among blacks are 
suggested. 
CONCLUSION 
It may be concluded from this study that chronic viral 
hepatitis infection is associated with elevated iron 
parameters especially in Hepatitis C infection. However, the 
prevalence of iron overload is low in this population. The 
study also showed that elevated iron parameters had 
minimal effect on degree of liver fibrosis.   Clinicians 
should therefore not rely on laboratory parameters alone in 
the true evaluation of iron overload, these should be 
combined with clinical findings. 
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